3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Your Basket's Financial Footprint
This basket's $14.60B total market cap is heavily anchored by a single large-cap holding, representing roughly 67.7% of the total, giving it a large-cap dominated profile.
- Large-cap dominance suggests generally lower volatility and returns aligned with broad market trends, reducing idiosyncratic risk.
- Suitable as a core holding, providing steady sector exposure rather than a speculative growth position.
- Expect steadier long-term appreciation; unlikely to deliver rapid, short-term explosive gains.
HUMA: $319.67M
CLGN: $30.14M
ORGO: $516.31M
- Other
About This Group of Stocks
Our Expert Thinking
We've identified companies at the intersection of 3D printing technology and biology that are creating functional human tissues. This emerging field targets massive opportunities in transplantation, personalized medicine, and pharmaceutical testing – potentially solving critical healthcare challenges like organ shortages.
What You Need to Know
This is a high-risk, high-reward investment focused on early-stage medical technology. Recent breakthroughs in creating vascular networks within printed tissues represent a critical advancement that could accelerate development and adoption. Consider this a satellite holding in a diversified portfolio.
Why These Stocks
We've carefully selected companies across the entire value chain – from pure-play tissue engineering firms to specialized 3D printer manufacturers and suppliers of critical biomaterials and technologies. This approach provides comprehensive exposure to this promising but still-developing field.
Why You'll Want to Watch These Stocks
Breakthrough Technology Moment
Recent advances in creating vascular networks within printed tissues represent a critical milestone that could accelerate development of larger, more complex organs and tissues.
Solving a $450B+ Problem
The global organ shortage affects millions of patients. These companies are pioneering solutions that could transform transplantation medicine and save countless lives.
Faster, Better Drug Development
Bioprinted human tissues provide pharmaceutical companies with more accurate models for drug testing, potentially reducing development costs and bringing new treatments to market sooner.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Drug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Automation & Software Investment Theme Overview
Recent labor data reveals a split market, with low private-sector jobless claims contrasting with high unemployment driven by federal layoffs. This dynamic creates an investment opportunity in companies providing automation, software, and efficiency-boosting services as businesses prioritize productivity over expanding their payrolls.
Oyo's IPO Plans: Hospitality Sector Recovery Explained
Global hospitality firm Oyo's parent company has revived its IPO plans, signaling renewed confidence in the travel market. This high-profile listing could ignite investor interest across the entire hospitality and travel technology sector, creating opportunities for related service providers.